- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment with novel oral anticoagulants
Authors
Keywords
-
Journal
CURRENT OPINION IN HEMATOLOGY
Volume 20, Issue 5, Pages 430-436
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2013-07-13
DOI
10.1097/moh.0b013e328363c170
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism
- (2013) Soheir S. Adam et al. ANNALS OF INTERNAL MEDICINE
- A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
- (2013) Genmin Lu et al. NATURE MEDICINE
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
- (2013) Alexander T. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
- (2013) Sam Schulman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban
- (2012) Tatjana S. Potpara et al. ADVANCES IN THERAPY
- Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation
- (2012) Corey S. Miller et al. AMERICAN JOURNAL OF CARDIOLOGY
- Dabigatran Association With Higher Risk of Acute Coronary Events
- (2012) Ken Uchino ARCHIVES OF INTERNAL MEDICINE
- Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation
- (2012) Takeshi Yamashita et al. CIRCULATION JOURNAL
- Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease
- (2012) John W. Eikelboom et al. Journal of Stroke & Cerebrovascular Diseases
- Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model
- (2012) I. PRAGST et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
- (2012) Raphael Marlu et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials
- (2012) José A. Nieto et al. THROMBOSIS RESEARCH
- Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
- (2012) A. Gomez-Outes et al. BMJ-British Medical Journal
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
- (2011) John W. Eikelboom et al. CIRCULATION
- Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate
- (2011) Elise S. Eerenberg et al. CIRCULATION
- Edoxaban
- (2011) A. John Camm et al. DRUGS
- DABIGATRAN ANTICOAGULANT ACTIVITY IS NEUTRALIZED BY AN ANTIBODY SELECTIVE TO DABIGATRAN IN IN VITRO AND IN VIVO MODELS
- (2011) Joanne van Ryn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
- (2011) Samuel Z. Goldhaber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban in Patients with Atrial Fibrillation
- (2011) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
- (2011) John H. Alexander et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)
- (2011) Ola Dahl et al. THROMBOSIS AND HAEMOSTASIS
- Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
- (2010) Christian T. Ruff et al. AMERICAN HEART JOURNAL
- Rivaroxaban: A New Oral Factor Xa Inhibitor
- (2010) Elisabeth Perzborn et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
- (2010) Koichiro Ogata et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
- (2010) T. FUJI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
- (2010) Michael Rud Lassen et al. LANCET
- Oral Rivaroxaban for Symptomatic Venous Thromboembolism
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
- (2010) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
- (2010) Stuart Connolly et al. THROMBOSIS AND HAEMOSTASIS
- Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
- (2010) Alexander Cohen et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
- (2010) Joachim Stangier et al. THROMBOSIS AND HAEMOSTASIS
- Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation
- (2010) Hui-Kyung Jeon et al. THROMBOSIS AND HAEMOSTASIS
- Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome
- (2009) CIRCULATION
- Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
- (2009) Joachim Stangier et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
- (2009) C. Weinz et al. DRUG METABOLISM AND DISPOSITION
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
- (2009) Sam Schulman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
- (2009) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
- (2008) et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
- (2008) Bengt I. Eriksson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
- (2008) Michael R. Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started